Literature DB >> 28289712

RCAN1-4 is a thyroid cancer growth and metastasis suppressor.

Chaojie Wang1,2, Motoyasu Saji1, Steven E Justiniano1, Adlina Mohd Yusof1, Xiaoli Zhang3, Lianbo Yu3, Soledad Fernández3, Paul Wakely4, Krista La Perle5, Hiroshi Nakanishi1, Neal Pohlman1, Matthew D Ringel1,2.   

Abstract

Metastasis suppressors are key regulators of tumor growth, invasion, and metastases. Loss of metastasis suppressors has been associated with aggressive tumor behaviors and metastatic progression. We previously showed that regulator of calcineurin 1, isoform 4 (RCAN1-4) was upregulated by the KiSS1 metastatic suppression pathway and could inhibit cell motility when overexpressed in cancer cells. To test the effects of endogenous RCAN1-4 loss on thyroid cancer in vivo, we developed RCAN1-4 knockdown stable cells. Subcutaneous xenograft models demonstrated that RCAN1-4 knockdown promotes tumor growth. Intravenous metastasis models demonstrated that RCAN1-4 loss promotes tumor metastases to the lungs and their subsequent growth. Finally, stable induction of RCAN1-4 expression reduced thyroid cancer cell growth and invasion. Microarray analysis predicted that nuclear factor, erythroid 2-like 3 (NFE2L3) was a pivotal downstream effector of RCAN1-4. NFE2L3 overexpression was shown to be necessary for RCAN1-4-mediated enhanced growth and invasiveness and NEF2L3 overexpression independently increased cell invasion. In human samples, NFE2L3 was overexpressed in TCGA thyroid cancer samples versus normal tissues and NFE2L3 overexpression was demonstrated in distant metastasis samples from thyroid cancer patients. In conclusion, we provide the first evidence to our knowledge that RCAN1-4 is a growth and metastasis suppressor in vivo and that it functions in part through NFE2L3.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28289712      PMCID: PMC5333959          DOI: 10.1172/jci.insight.90651

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  54 in total

1.  SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis.

Authors:  Sait Ozturk; Panagiotis Papageorgis; Chen Khuan Wong; Arthur W Lambert; Hamid M Abdolmaleky; Arunthathi Thiagalingam; Herbert T Cohen; Sam Thiagalingam
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-06       Impact factor: 11.205

Review 2.  Transcriptional regulation by calcium, calcineurin, and NFAT.

Authors:  Patrick G Hogan; Lin Chen; Julie Nardone; Anjana Rao
Journal:  Genes Dev       Date:  2003-09-15       Impact factor: 11.361

3.  Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model.

Authors:  Dong Keun Rhee; Su Hyung Park; Yeun Kyu Jang
Journal:  Genomics       Date:  2008-10-09       Impact factor: 5.736

4.  Growth regulation of normal thyroids and thyroid tumors in man.

Authors:  P E Goretzki; A Frilling; D Simon; H D Roeher
Journal:  Recent Results Cancer Res       Date:  1990

5.  Risks of leukaemia and solid tumours in individuals with Down's syndrome.

Authors:  H Hasle; I H Clemmensen; M Mikkelsen
Journal:  Lancet       Date:  2000-01-15       Impact factor: 79.321

6.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

7.  A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth.

Authors:  Robert L Plews; Adlina Mohd Yusof; Chaojie Wang; Motoyasu Saji; Xiaoli Zhang; Ching-Shih Chen; Matthew D Ringel; John E Phay
Journal:  J Clin Endocrinol Metab       Date:  2015-02-24       Impact factor: 5.958

Review 8.  Metastasis suppressors genes in cancer.

Authors:  Lewis J Stafford; Kedar S Vaidya; Danny R Welch
Journal:  Int J Biochem Cell Biol       Date:  2008-01-15       Impact factor: 5.085

9.  Coexpression of functionally active receptors for thyrotropin and platelet-derived growth factor in human thyroid carcinoma cells.

Authors:  N E Heldin; D Cvejić; S Smeds; B Westermark
Journal:  Endocrinology       Date:  1991-10       Impact factor: 4.736

10.  Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo.

Authors:  Enrico Caserta; Onur Egriboz; Hui Wang; Chelsea Martin; Christopher Koivisto; Thierry Pecót; Raleigh D Kladney; Changxian Shen; Kang-Sup Shim; Thac Pham; Matthew K Karikomi; Melissa J Mauntel; Sarmila Majumder; Maria C Cuitino; Xing Tang; Arunima Srivastava; Lianbo Yu; Julie Wallace; Xiaokui Mo; Morag Park; Soledad A Fernandez; Robert Pilarski; Krista M D La Perle; Thomas J Rosol; Vincenzo Coppola; Diego H Castrillon; Cynthia Timmers; David E Cohn; David M O'Malley; Floor Backes; Adrian A Suarez; Paul Goodfellow; Helen M Chamberlin; Erin R Macrae; Charles L Shapiro; Michael C Ostrowski; Gustavo Leone
Journal:  Genes Dev       Date:  2015-08-15       Impact factor: 11.361

View more
  19 in total

Review 1.  Coding Molecular Determinants of Thyroid Cancer Development and Progression.

Authors:  Veronica Valvo; Carmelo Nucera
Journal:  Endocrinol Metab Clin North Am       Date:  2018-12-23       Impact factor: 4.741

2.  MiR-4674 regulates angiogenesis in tissue injury by targeting p38K signaling in endothelial cells.

Authors:  Basak Icli; Hao Li; Daniel Pérez-Cremades; Winona Wu; Denizhan Ozdemir; Stefan Haemmig; Raphael Boesch Guimaraes; Andre Manica; Julio F Marchini; Dennis P Orgill; Mark W Feinberg
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

3.  MicroRNA-615-5p Regulates Angiogenesis and Tissue Repair by Targeting AKT/eNOS (Protein Kinase B/Endothelial Nitric Oxide Synthase) Signaling in Endothelial Cells.

Authors:  Basak Icli; Winona Wu; Denizhan Ozdemir; Hao Li; Henry S Cheng; Stefan Haemmig; Xin Liu; Giorgio Giatsidis; Seyma Nazli Avci; Nathan Lee; Raphael Boesch Guimaraes; Andre Manica; Julio F Marchini; Stein Erik Rynning; Ivar Risnes; Ivana Hollan; Kevin Croce; Xianbin Yang; Dennis P Orgill; Mark W Feinberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-05-16       Impact factor: 8.311

Review 4.  RCAN1-mediated calcineurin inhibition as a target for cancer therapy.

Authors:  Mengyi Lao; Xiaozhen Zhang; Hanshen Yang; Xueli Bai; Tingbo Liang
Journal:  Mol Med       Date:  2022-06-18       Impact factor: 6.376

5.  Common pathways and functional profiles reveal underlying patterns in Breast, Kidney and Lung cancers.

Authors:  Sergio Romera-Giner; Zoraida Andreu Martínez; Francisco García-García; Marta R Hidalgo
Journal:  Biol Direct       Date:  2021-05-26       Impact factor: 4.540

6.  STAT3-regulated LncRNA LINC00160 mediates cell proliferation and cell metabolism of prostate cancer cells by repressing RCAN1 expression.

Authors:  Wenjing Zhu; Dongya Sheng; Yiqun Shao; Qiang Zhang; Yu Peng
Journal:  Mol Cell Biochem       Date:  2022-01-24       Impact factor: 3.396

7.  Cancer risk susceptibility loci in a Swedish population.

Authors:  Wen Liu; Xiang Jiao; Jessada Thutkawkorapin; Hovsep Mahdessian; Annika Lindblom
Journal:  Oncotarget       Date:  2017-11-25

8.  NFE2L3 Inhibition Induces Cell Cycle Arrest at the G0/G1 Phase in Colorectal Cancer Cells through Downregulating CCND1 and pRb1-ser807/811.

Authors:  Lihua Zhang; Dong-Li Hu; Baiyou Tang; Yu Cheng; Chuan Jiao; Lin Cheng; Zhi-Rong Tan; Hong-Hao Zhou
Journal:  Dis Markers       Date:  2019-05-05       Impact factor: 3.434

9.  RCAN1 in the inverse association between Alzheimer's disease and cancer.

Authors:  Qiang Fu; Yili Wu
Journal:  Oncotarget       Date:  2017-12-11

10.  The RCAN1.4-calcineurin/NFAT signaling pathway is essential for hypoxic adaption of intervertebral discs.

Authors:  Bao Huang; Yongqing He; Shengwen Li; Xiaoan Wei; Junhui Liu; Zhi Shan; Yue Huang; Jian Chen; Fengdong Zhao
Journal:  Exp Mol Med       Date:  2020-05-29       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.